JP2003522185A5 - - Google Patents

Download PDF

Info

Publication number
JP2003522185A5
JP2003522185A5 JP2001557903A JP2001557903A JP2003522185A5 JP 2003522185 A5 JP2003522185 A5 JP 2003522185A5 JP 2001557903 A JP2001557903 A JP 2001557903A JP 2001557903 A JP2001557903 A JP 2001557903A JP 2003522185 A5 JP2003522185 A5 JP 2003522185A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
solubility tag
acid residues
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001557903A
Other languages
English (en)
Japanese (ja)
Other versions
JP4896333B2 (ja
JP2003522185A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/003813 external-priority patent/WO2001057072A2/en
Publication of JP2003522185A publication Critical patent/JP2003522185A/ja
Publication of JP2003522185A5 publication Critical patent/JP2003522185A5/ja
Application granted granted Critical
Publication of JP4896333B2 publication Critical patent/JP4896333B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001557903A 2000-02-07 2001-02-06 薬理活性抗ウイルスペプチドおよびそれらの使用法 Expired - Fee Related JP4896333B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18082300P 2000-02-07 2000-02-07
US60/180,823 2000-02-07
US18405700P 2000-02-22 2000-02-22
US60/184,057 2000-02-22
PCT/US2001/003813 WO2001057072A2 (en) 2000-02-07 2001-02-06 Pharmacologically active antiviral peptides and methods of their use

Publications (3)

Publication Number Publication Date
JP2003522185A JP2003522185A (ja) 2003-07-22
JP2003522185A5 true JP2003522185A5 (enExample) 2011-04-21
JP4896333B2 JP4896333B2 (ja) 2012-03-14

Family

ID=26876670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001557903A Expired - Fee Related JP4896333B2 (ja) 2000-02-07 2001-02-06 薬理活性抗ウイルスペプチドおよびそれらの使用法

Country Status (9)

Country Link
US (3) US7371809B2 (enExample)
EP (1) EP1272510B1 (enExample)
JP (1) JP4896333B2 (enExample)
AT (1) ATE374208T1 (enExample)
AU (1) AU784264B2 (enExample)
CA (1) CA2399676C (enExample)
DE (1) DE60130641T2 (enExample)
ES (1) ES2293977T3 (enExample)
WO (1) WO2001057072A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272510B1 (en) 2000-02-07 2007-09-26 Wisconsin Alumni Research Foundation Pharmacologically active antiviral peptides and methods of their use
US7094413B2 (en) * 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
US7432045B2 (en) 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides
JP4831410B2 (ja) 2006-02-28 2011-12-07 東亞合成株式会社 抗ウイルス性ペプチドおよび抗ウイルス剤
CA2727898A1 (en) 2008-06-13 2009-12-17 Wisconsin Alumni Research Foundation Novel antiviral peptides against influenza virus
WO2009152518A1 (en) * 2008-06-13 2009-12-17 Wisconsin Alumni Research Foundation Novel peptide adjuvant for influenza vaccination
AU2009292959B2 (en) * 2008-09-19 2016-02-25 Henry Ford Health System Methods, systems, and compositions for calpain inhibition
GB201012651D0 (en) * 2010-07-28 2010-09-15 Univ Edinburgh Peptides
WO2012071549A2 (en) 2010-11-24 2012-05-31 Clontech Laboratories, Inc. Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same
US20120190107A1 (en) * 2011-01-26 2012-07-26 Dwayne Bisgrove Enhanced protein transduction
ES2444299B1 (es) 2012-08-23 2014-12-12 Nutrición Técnica Deportiva, S.L. Uso de un hidrolizado de caseina como agente antiherpético
KR20200012894A (ko) 2017-05-26 2020-02-05 비라매틱스 에스디엔 비에이치디 펩타이드 및 항바이러스제로서의 이의 용도
KR20240067073A (ko) * 2021-08-23 2024-05-16 아미트렉스 테라퓨틱스, 인크. 백혈구 특이적 세포 투과 분자

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795740A (en) * 1986-05-20 1989-01-03 Cohen Eric A Antiviral peptides and means for treating herpes infections
US4814432A (en) 1987-05-22 1989-03-21 Merck & Co., Inc. Inhibitor of ribonucleotide reductase
US5260420A (en) * 1987-07-30 1993-11-09 Centre Regional De Transfusion Sanguine De Lille Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
US5104854A (en) * 1989-02-01 1992-04-14 Washington University Antiviral peptides
CA1340682C (en) * 1989-07-07 1999-07-27 Pierre Lavallee Antiviral peptides having a 2-oxoalkyl amino acid side chain
IT1231342B (it) * 1989-08-28 1991-11-28 Prodotti Antibiotici Spa Derivati peptidici farmacologicamente attivi e preparazioni farmaceutiche che li contengono
JPH0421635A (ja) 1990-05-16 1992-01-24 Suntory Ltd アセトアルデヒドの毒性抑制剤およびアセトアルデヒドの毒性抑制に有効な飲食物
CA2033447C (en) * 1990-12-31 1999-08-31 Robert Deziel Synergistic combination for treating herpes infections
EP0531080A3 (en) 1991-09-04 1993-12-29 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene protein
EP0726749B1 (en) * 1993-11-03 2004-08-11 Clarion Pharmaceuticals, Inc. Hemostatic patch
US5441936A (en) * 1993-12-07 1995-08-15 Houghten Pharmaceuticals, Inc. Antiviral peptides
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
AU3982497A (en) 1996-07-30 1998-02-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Double-stranded rna dependent protein kinase derived peptides to promote proliferation of cells and tissues in controlled manner
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
AU6972798A (en) * 1997-04-18 1998-11-13 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
WO1999005302A1 (en) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugates of transporter peptides and nucleic acid analogs, and their use
FR2766826B1 (fr) * 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
WO1999064449A2 (en) * 1998-06-10 1999-12-16 The Queen's University Of Belfast Cell-permeable peptide
EP1272510B1 (en) 2000-02-07 2007-09-26 Wisconsin Alumni Research Foundation Pharmacologically active antiviral peptides and methods of their use
US7432045B2 (en) 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides

Similar Documents

Publication Publication Date Title
JP2003522185A5 (enExample)
JP2005516885A5 (enExample)
JPH08504837A (ja) 新規ポリペプチドおよびこれから調製される抗ｈｉｖ剤
EP0528312A3 (en) Cyclic peptides and use thereof
JPH1072351A5 (enExample)
JP2005505579A5 (enExample)
EP0502198B1 (en) Novel polypeptide and anti-hiv drug prepared therefrom
JP2006506942A5 (enExample)
WO2004108938A3 (en) Peptide ligands of dendritic cells for nucleic acid vector targeting
CA2391333A1 (en) Sustained release formulation of a peptide and a copolymer
JP4808363B2 (ja) 新規ポリペプチド及びこれを含む抗ｈｉｖ剤
CN102336815A (zh) 病毒感染的治疗
WO2004099240B1 (en) Peptides and mixtures thereof for use in the detection of severe acute respiratory syndrome-associated coronavirus (sars)
CA2399676A1 (en) Pharmacologically active antiviral peptides and methods of their use
JP2006503088A5 (enExample)
AU671989B2 (en) Treatment of tropical spastic paresis with peptide T
US5622933A (en) Multiple branch peptide constructions for use against HIV
EP2990415B1 (en) Cyclic beta defensins analogs for the treatment of infections
JP2010511706A5 (enExample)
JP2006510360A5 (enExample)
WO2003097677A3 (fr) Nouvelles compostions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
CA2088788C (en) Peptides that block human immunodeficiency virus infections and methods of use thereof
JP4332618B2 (ja) 抗ｈｉｖ剤
NZ508812A (en) Peptides for the prevention or treatment of HIV